MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563722 | Name: OB-24 HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

OB-24 HCl is a potent and selective heme oxygenase 1 (HO-1) inhibitor.

Chemical Structure

OB-24 HCl
OB-24 HCl
CAS#939825-12-4

Theoretical Analysis

MedKoo Cat#: 563722

Name: OB-24 HCl

CAS#: 939825-12-4

Chemical Formula: C15H18BrClN2O2

Exact Mass: 0.0000

Molecular Weight: 373.68

Elemental Analysis: C, 48.21; H, 4.86; Br, 21.38; Cl, 9.49; N, 7.50; O, 8.56

Price and Availability

Size Price Availability Quantity
50mg USD 550.00 2 Weeks
100mg USD 950.00 2 Weeks
1g USD 4,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
OB-24 hydrochloride; OB-24 HCl; OB 24 HCl; OB24 HCl;
IUPAC/Chemical Name
1-[[2-[2-(4-Bromophenyl)ethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazole hydrochloride
InChi Key
YSOWYXRHOAXXTG-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H17BrN2O2.ClH/c16-14-3-1-13(2-4-14)5-6-15(19-9-10-20-15)11-18-8-7-17-12-18;/h1-4,7-8,12H,5-6,9-11H2;1H
SMILES Code
BrC1=CC=C(CCC2(CN3C=CN=C3)OCCO2)C=C1.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
OB-24 is a potent inhibitor of heme oxygenase-1 (HO-1).
In vitro activity:
The effect of ho-1 silencing on these oncogenic features was mimicked by exposure of cells to a novel selective small-molecule HO-1 inhibitor referred to as OB-24. OB-24 selectively inhibited HO-1 activity in PCA cells, which correlated with a reduction of protein carbonylation and reactive oxygen species formation. Moreover, OB-24 significantly inhibited cell proliferation in vitro and tumor growth and lymph node/lung metastases in vivo. Reference: Cancer Res. 2009 Oct 15;69(20):8017-24. https://pubmed.ncbi.nlm.nih.gov/19808972/
In vivo activity:
The effect of ho-1 silencing on these oncogenic features was mimicked by exposure of cells to a novel selective small-molecule HO-1 inhibitor referred to as OB-24. OB-24 selectively inhibited HO-1 activity in PCA cells, which correlated with a reduction of protein carbonylation and reactive oxygen species formation. Moreover, OB-24 significantly inhibited cell proliferation in vitro and tumor growth and lymph node/lung metastases in vivo. Reference: Cancer Res. 2009 Oct 15;69(20):8017-24. https://pubmed.ncbi.nlm.nih.gov/19808972/
Solvent mg/mL mM
Solubility
DMSO 37.4 100.00
Water 37.4 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 373.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009 Oct 15;69(20):8017-24. doi: 10.1158/0008-5472.CAN-09-0419. Epub 2009 Oct 6. PMID: 19808972.
In vitro protocol:
Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009 Oct 15;69(20):8017-24. doi: 10.1158/0008-5472.CAN-09-0419. Epub 2009 Oct 6. PMID: 19808972.
In vivo protocol:
Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009 Oct 15;69(20):8017-24. doi: 10.1158/0008-5472.CAN-09-0419. Epub 2009 Oct 6. PMID: 19808972.
1: Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009 Oct 15;69(20):8017-24. doi: 10.1158/0008-5472.CAN-09-0419. Epub 2009 Oct 6. PubMed PMID: 19808972. 2: Gater D, Macauley D. American Chemical Society--238th National Meeting & Exposition. Developments in medicinal chemistry: part 2. 16-20 August 2009, Washington DC, USA. IDrugs. 2009 Oct;12(10):608-11. PubMed PMID: 19790005.